Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice
Journal of Clinical Oncology · 20.02.2025 · 43 (6) · 682-693
DOI: 10.1200/jco.23.02761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2025. Verfasst von Ivone U S Leong und 35 weiteren Autor:innen. Beteiligte Einrichtung: Genomics England Ltd, Level 21 One Canada Square, London, United Kingdom. Hauptthemen laut MEDLINE: Neoplasms, Whole Genome Sequencing, Pharmacogenetics, Pharmacogenomic Testing. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
PURPOSE As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service. METHODS Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes ( DPYD , NUDT15 , TPMT , UGT1A1 ) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants. In a subset of 7,081 patients with cancer, DPYD variants were reported back to clinicians and outcomes were collected. RESULTS We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these PGx variants, approximately 14,540 patients per year could potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs. Validating PGx associations in a real-world data set, we found a significant association between PGx variants in DPYD and toxicity-related phenotypes in patients treated with capecitabine or fluorouracil. Reported DPYD variants were deemed informative for clinical decision making in a majority of cases. CONCLUSION Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genomics England Ltd, Level 21 One Canada Square, London, United Kingdom.
- Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
- NIHR Barts Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
- Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
- Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
- Wolfson Centre for Personalised Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Claudia P Cabrera, Valentina Cipriani, Paul J Ross, Richard M Turner, Alex Stuckey, Sonali Sanghvi, Loukas Moutsianas, Christopher A Odhams, Greg S Elgar, Georgia Chan, Susan Walker, Rebecca E Foulger, Eleanor M Williams, Louise C Daugherty, Daniel J Rhodes, Olivia Niblock, Sarah E A Leigh, Matthew J Welland, Marta Bleda, Catherine Snow, Zandra Deans, Nirupa Murugaesu, Richard H Scott, Michael R Barnes, Matthew A Brown, Alona Sosinsky, Mark J Caulfield, Ellen M McDonagh
Förderung
- Wellcome Trust
Zitieren
APA
Leong, I. U. S., Cabrera, C. P., Cipriani, V., Ross, P. J., Turner, R. M., Stuckey, A., Sanghvi, S., Pasko, D., Moutsianas, L., Odhams, C. A., Elgar, G. S., Chan, G., Giess, A., Walker, S., Foulger, R. E., Williams, E. M., Daugherty, L. C., Rueda-Martin, A., Rhodes, D. J., …, & McDonagh, E. M. (2025). Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice. Journal of Clinical Oncology, 43(6), 682-693. https://doi.org/10.1200/jco.23.02761
Vancouver
Leong IUS, Cabrera CP, Cipriani V, Ross PJ, Turner RM, Stuckey A, et al. Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice. Journal of Clinical Oncology. 2025;43(6):682-693. doi:10.1200/jco.23.02761
BibTeX
@article{Leong2025,
author = {Leong, Ivone U S and Cabrera, Claudia P and Cipriani, Valentina and Ross, Paul J and Turner, Richard M and Stuckey, Alex and Sanghvi, Sonali and Pasko, Dorota and Moutsianas, Loukas and Odhams, Christopher A and Elgar, Greg S and Chan, Georgia and Giess, Adam and Walker, Susan and Foulger, Rebecca E and Williams, Eleanor M and Daugherty, Louise C and Rueda-Martin, Antonio and Rhodes, Daniel J and Niblock, Olivia and Pickard, Alexandra and Marks, Lauren and Leigh, Sarah E A and Welland, Matthew J and Bleda, Marta and Snow, Catherine and Deans, Zandra and Murugaesu, Nirupa and Scott, Richard H and Barnes, Michael R and Brown, Matthew A and Rendon, Augusto and Hill, Sue and Sosinsky, Alona and Caulfield, Mark J and McDonagh, Ellen M},
title = {Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {6},
pages = {682--693},
doi = {10.1200/jco.23.02761}
}
EUVIMED